Merck

(IN BRIEF) Merck KGaA, Darmstadt, Germany, has entered into a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds, currently under Phase II evaluation for the second-line … Read the full press release →

(IN BRIEF) Merck has completed the second phase of its new €29 million Biologics Testing Center in China, adding 1,500 square meters to the facility. This expansion includes the first biosafety laboratories for Merck in the Chinese market, enabling clients … Read the full press release →

(IN BRIEF) AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has gained approval from the US Food and Drug Administration (FDA) for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer possessing specific … Read the full press release →

(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab), in combination with transarterial chemoembolisation (TACE) and bevacizumab, significantly improves progression-free survival (PFS) in patients with hepatocellular carcinoma (HCC) eligible … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, has entered into a strategic partnership with Jiangsu Hengrui Pharmaceuticals. This collaboration includes an exclusive global license (excluding China) to develop and commercialize Hengrui’s advanced PARP1 inhibitor, HRS-1167. Additionally, there is … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, has announced its expectation to return to organic sales growth in fiscal 2024. This was revealed during the company’s Capital Markets Day. Despite challenging market conditions in its Life Science and … Read the full press release →

(IN BRIEF) Merck, a leading science and technology company, is set to present 28 abstracts at the 2023 European Society of Medical Oncology (ESMO) Annual Meeting in Madrid. These abstracts will showcase the latest research on Merck’s oncology portfolio, addressing … Read the full press release →

(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO) Congress, demonstrating advances in cancer treatments across multiple types of cancers. These trials include TROPION-Lung01 and TROPION-Breast01, showcasing the significance … Read the full press release →

(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The data from an ongoing Phase II open-label extension study of evobrutinib in patients with relapsing multiple sclerosis (RMS) show sustained … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, has revealed new findings from the MAVENCLAD® (cladribine tablets) MAGNIFY-MS study at the 9th Joint ECTRIMS-ACTRIMS meeting in Milan. The study demonstrated that patients with relapsing multiple sclerosis (RMS) experienced a … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, has entered into a collaboration with the United Nations’ Global Initiative on Ageing (GIA) to offer a training course aimed at equipping family carers with essential skills. The course comprises five … Read the full press release →

(IN BRIEF) TotalEnergies has inked a 15-year Renewable Power Purchase Agreement (PPA) with Saint-Gobain, marking the second long-term solar power supply agreement aimed at decarbonizing the building materials company’s 125 industrial sites in North America. TotalEnergies will provide clean energy … Read the full press release →

(IN BRIEF) Merck, a prominent science and technology company, has announced strategic drug discovery collaborations with AI technology firms BenevolentAI and Exscientia. These partnerships aim to leverage AI-driven design and discovery capabilities to advance research efforts in key therapeutic areas, … Read the full press release →

(IN BRIEF) AstraZeneca’s new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review by the US FDA for the treatment of advanced breast cancer. The NDA is being reviewed under Project Orbis, which … Read the full press release →

(IN BRIEF) Merck will showcase innovative ideas and new products for the paint and coatings industry at the European Coatings Show 2023 in Germany. One of the highlights will be the latest pigment development from the company that enables Surface … Read the full press release →

(IN BRIEF) Merck and Intel have signed a memorandum of understanding to invest in a new academic research program aimed at driving innovation in semiconductor manufacturing processes and technologies using artificial intelligence (AI) and machine learning. The companies will jointly … Read the full press release →

(COMMUNIQUÉ DE PRESSE) DARMSTADT, 24-Jan-2022 — /EuropaWire/ — Merck (ETR : MRK), une multinationale allemande leader dans le domaine scientifique et société technologique spécialisée dans les soins de santé, les sciences de la vie et l’électronique, a annoncé que la société … Read the full press release →

(PRESS RELEASE) DARMSTADT, 24-Jan-2022 — /EuropaWire/ — Merck (ETR: MRK), a German multinational leading science and technology company in healthcare, life science, electronics, has announced the company hit a milestone mark in its donation of praziquantel for the treatment of … Read the full press release →

(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. ​​This … Read the full press release →

An innovative solution seamlessly integrates trade finance, cash management and FX needs, into a single, streamlined and automated workflow (PRESS RELEASE) FRANKFURT AM  MAIN, 2-Dec-2021 — /EuropaWire/ — Deutsche Bank (ETR: DBK), Germany’s leading multinational investment bank and financial services … Read the full press release →